Du är här

2016-02-22

Novavax, Inc.: Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced it will report its fourth quarter and full year
2015 financial and operating results prior to the open of U.S. financial
markets on Monday, February 29, 2016.

Management will host a conference call to discuss the quarterly and year-end
financial results and provide an update on corporate activities.

Conference call details are as follows:

--------------------------------------------------------------------------------
| Date: February 29, 2016 |
| Time: 8:00 am U.S. Eastern Time (ET) |
| Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Via web: www.novavax.com, "Investors"/ "Events" |
| |
--------------------------------------------------------------------------------
Conference call replay:

--------------------------------------------------------------------------------------------
| Dates: Starting at 11:00 am ET, February 29, 2016 until midnight March 7, 2016 |
| Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: 45346424 |
| Via web: www.novavax.com, "Investors"/ "Events" |
| |
--------------------------------------------------------------------------------------------
About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines.
Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1988185

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.